| Accession |
PRJCA010775 |
| Title |
CheckMate 914: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 914 |
| Relevance |
Medical |
| Data types |
biomaker PD-L1/MDSC
|
| Organisms |
Homo sapiens
|
| Description |
The study aims to explore the role of the nivolumab and ipilimumab combination compared to placebo and the role of nivolumab monotherapy compared to placebo post-surgery inadded efficacy and safety in preventing disease recurrence and the impact on survival. If the safety profile is acceptable and nivolumab monotherapy or nivolumab combined with ipilimumab is shown to improve DFS, this study would support the approval of nivolumab or nivolumab combined with ipilimumab in treatment-naive advanced RCC patients post-surgery |
| Sample scope |
Multiisolate |
| Release date |
2022-07-25 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Bristol-Myers Squibb (China) Investment Co., Ltd., Bristol-Myers Squibb Company
|
|
2017L04825/2017L04826
|
|
|
|
| Submitter |
JIAN
HUANG (hjgcp2017@163.com)
|
| Organization |
Sun Yat-sen Memorial Hospital, Sun Yat-sen University |
| Submission date |
2022-07-25 |
